Effectiveness of pulmonary rehabilitation on functional exercise capacity & health related quality of life (HRQOL) among individuals with post tuberculosis lung disease: A multicentric pre & post-interventional study.

Publisher: Scientific Scholar Country of Publication: United States NLM ID: 0374701 Publication Model: Print Cited Medium: Internet ISSN: 0971-5916 (Print) Linking ISSN: 09715916 NLM ISO Abbreviation: Indian J Med Res Subsets: MEDLINE

Publication: 2024- : [Pittsford, NY] : Scientific Scholar
Original Publication: New Delhi : Council Of Medical Research

Tuberculosis, Pulmonary*/physiopathology ; Tuberculosis, Pulmonary*/rehabilitation ; Tuberculosis, Pulmonary*/complications ; Pulmonary Disease, Chronic Obstructive*/physiopathology ; Pulmonary Disease, Chronic Obstructive*/rehabilitation ; Lung Diseases, Interstitial*/physiopathology ; Lung Diseases, Interstitial*/rehabilitation; Exercise Tolerance/physiology ; Exercise Therapy/methods ; India/epidemiology ; Lung/physiopathology ; Humans ; Quality of Life ; Male ; Female ; Middle Aged ; Adult ; Aged

Background & objectives Pulmonary rehabilitation (PR) has been extensively studied and proven beneficial in various respiratory conditions such as chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Individuals with post-tuberculosis lung disease (P-TBLD) have limited exercise tolerance and a significant disability affecting daily living, much like those with COPD. Hence, they appear to be good candidates for PR. This study aimed to determine the effectiveness of an outpatient PR protocol on functional exercise capacity and health-related quality of life (HRQOL) in individuals with P-TBLD. Furthermore, the effectiveness of adherence to the PR protocol among the participants as well as identifying the gaps and barriers in accessing PR were also determined. Methods This is a multicentric pre- and post-interventional study conducted across five centres in India. 260 individuals with P-TBLD were included if they could complete more than 80 per cent of the physiotherapist's training sessions at the time of enrollment had previously received treatment for pulmonary tuberculosis and were negative for acid fast bacilli (AFB) on sputum examination. Individuals were excluded if they had preexisting lung disease other than P-TBLD or suffered from any mental, neurological, musculoskeletal, or unstable cardiovascular disease that could impair their performance during the exercise training sessions. Pre- and post-intervention assessments included clinical symptoms, exercise intolerance, pulmonary function test (PFT), 6-minute walk test (6MWT), muscle strength testing, and St. George Respiratory Questionnaire (SGRQ) score for HRQOL. Participants received PR training at first visit in OPD and were advised to follow it at home and telephonic follow up was done for a duration of 12 wk. Results Out of the 260 participants who were enrolled, 246 patients completed the post-intervention evaluation following 12 wk of the PR protocol. Clinical parameters, the 6MWT, the functional balance test, and the muscle strength test all showed significant improvement after PR. Significant improvement was observed across all domains of the SGRQ score. Pulmonary function measures showed significant improvement in FEV1 and FVC parameters post intervention. Interpretation & conclusions This study provides compelling evidence that PR is beneficial for post-TB patient, leading to notable improvements in the exercise capacity, symptom management as well as the overall quality of life. The findings support the implementation of PR protocol on a larger scale within national health frameworks, particularly in countries with high TB prevalence. By integrating PR into the National Tuberculosis Elimination Programme, it is possible to offer a comprehensive care approach that sets standard indicators for the surveillance of P-TBLD and addresses the long-term health needs of TB survivors.

J Bras Pneumol. 2019 Apr 25;45(2):e20180324. (PMID: 31038649)
J Physiother. 2022 Apr;68(2):90-98. (PMID: 35414491)
Med J Armed Forces India. 2022 Apr;78(2):164-169. (PMID: 35463544)
Cochrane Database Syst Rev. 2022 Aug 22;8:CD013485. (PMID: 35993916)
Int J Chron Obstruct Pulmon Dis. 2022 Jan 13;17:141-153. (PMID: 35046649)
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. (PMID: 12091180)
Respir Med. 2012 Mar;106(3):374-81. (PMID: 22000501)
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. (PMID: 24127811)
Int J Chron Obstruct Pulmon Dis. 2017 Dec 11;12:3533-3539. (PMID: 29270007)
Chron Respir Dis. 2011;8(2):89-99. (PMID: 21596892)
Int J Tuberc Lung Dis. 2020 Aug 1;24(8):820-828. (PMID: 32912387)
Lancet Glob Health. 2021 Dec;9(12):e1679-e1687. (PMID: 34798027)
Cochrane Database Syst Rev. 2017 Nov 01;11:CD002768. (PMID: 29090734)
Eur Respir J. 2019 Mar 14;53(3):. (PMID: 30872556)
Int J Chron Obstruct Pulmon Dis. 2021 Aug 10;16:2291-2299. (PMID: 34408411)
Afr Health Sci. 2014 Dec;14(4):866-72. (PMID: 25834495)
Respir Med. 2016 May;114:67-71. (PMID: 27109813)
Cochrane Database Syst Rev. 2021 Feb 1;2:CD006322. (PMID: 34559419)
Chest. 2007 May;131(5 Suppl):4S-42S. (PMID: 17494825)
Chest. 2007 Jun;131(6):1817-24. (PMID: 17400690)
EClinicalMedicine. 2023 Mar 10;57:101900. (PMID: 36942158)
Chest. 2003 Jun;123(6):1988-95. (PMID: 12796179)
Int J Tuberc Lung Dis. 2023 Apr 1;27(4):248-283. (PMID: 37035971)
Eur Respir Rev. 2023 Apr 19;32(168):. (PMID: 37076175)
Health Qual Life Outcomes. 2009 Feb 18;7:14. (PMID: 19224645)
Cureus. 2018 Nov 30;10(11):e3664. (PMID: 30755839)
Intern Med. 2006;45(6):399-403. (PMID: 16617192)
AJR Am J Roentgenol. 2001 Feb;176(2):441-5. (PMID: 11159091)
J Family Med Prim Care. 2021 Sep;10(9):3411-3416. (PMID: 34760766)
J Bras Pneumol. 2020 Mar 2;46(2):e20180198. (PMID: 32130330)
Cochrane Database Syst Rev. 2023 Mar 22;3:CD011285. (PMID: 36947725)
Indian J Tuberc. 2024 Apr;71(2):123-129. (PMID: 38589115)
Int J Tuberc Lung Dis. 2007 Aug;11(8):887-92. (PMID: 17705955)
Cochrane Database Syst Rev. 2021 Jan 29;1:CD013040. (PMID: 33511633)
Thorac Res Pract. 2023 May;24(3):131-136. (PMID: 37503614)
Lancet Infect Dis. 2021 Jul;21(7):984-992. (PMID: 33640076)
Am J Respir Crit Care Med. 2015 Dec 1;192(11):1373-86. (PMID: 26623686)
J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. (PMID: 27812638)
Lung Cancer. 2011 May;72(2):139-53. (PMID: 21316790)

Keywords: 6-minute walk test; HRQOL; TB; pulmonary function test; pulmonary rehabilitation; tuberculosis

Date Created: 20250822 Date Completed: 20250822 Latest Revision: 20260502

20260502

PMC12550408

10.25259/IJMR_1643_2024

40844105